Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis

Background Aortic stiffness index (AoSI) has to be considered a proxy outcome measure in patients with rheumatoid arthritis (RA). The aim of this study was to comparatively describe AoSI progression in two groups of RA patients on long-term treatment with conventional synthetic disease-modifying ant...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis research & therapy 2021-06, Vol.23 (1), p.1-158, Article 158
Main Authors: Giollo, Alessandro, Cioffi, Giovanni, Ognibeni, Federica, Orsolini, Giovanni, Dalbeni, Andrea, Bixio, Riccardo, Adami, Giovanni, Fassio, Angelo, Idolazzi, Luca, Gatti, Davide, Rossini, Maurizio, Viapiana, Ombretta
Format: Article
Language:English
Subjects:
Arteriosclerosis
Arthritis
Blood pressure
Body mass index
Cardiovascular disease
Cholesterol
Drug therapy
Inflammation
Lipids
Mortality
Necrosis
Patient outcomes
Population
Rheumatoid arthritis
Risk factors
Triglycerides
Tumor necrosis factor inhibitors
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Aortic stiffness index (AoSI) has to be considered a proxy outcome measure in patients with rheumatoid arthritis (RA). The aim of this study was to comparatively describe AoSI progression in two groups of RA patients on long-term treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with or without tumour necrosis factor inhibitors (TNFi). Methods AoSI was evaluated by Doppler echocardiography at the level of the aortic root, using a two-dimensional guided M-mode evaluation. Eligible participants were assessed at baseline and after 12 months. Changes in serum lipids, glucose and arterial blood pressure were assessed. All patients who did not change DMARD treatment during follow-up were consecutively selected for this study. Results We included 107 (64 TNFi and 43 csDMARDs) RA patients. Most patients (74%) were in remission or low disease activity and had some CVD risk factors (45.8% hypertension, 59.8% dyslipidaemia, 45.3% smoking). The two groups did not differ significantly for baseline AoSI (5.95[+ or -]3.73% vs 6.08[+ or -]4.20%, p=0.867). Follow-up AoSI was significantly increased from baseline in the csDMARDs group (+1.00%; p
ISSN:1478-6362
1478-6354
1478-6362
DOI:10.1186/s13075-021-02546-3